semaglutide cardiovascular risk Effects of on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6 Wegovy confers reductions in cardiovascular
Description
FDA approved December 2017, MHRA 2018
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target
Diabetology & Metabolic Syndrome , 16 (1)
Transform supply chain Secure flexible co-packing and dual-source key inputs
